7-124858989-C-T

Variant summary

Our verdict is Uncertain significance. Variant got 2 ACMG points: 2P and 0B. PP3_Moderate

The NM_015450.3(POT1):​c.670G>A​(p.Asp224Asn) variant causes a missense change. The variant allele was found at a frequency of 0.00017 in 1,610,988 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. D224G) has been classified as Uncertain significance.

Frequency

Genomes: 𝑓 0.00011 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00018 ( 1 hom. )

Consequence

POT1
NM_015450.3 missense

Scores

9
7
3

Clinical Significance

Uncertain significance criteria provided, multiple submitters, no conflicts P:1U:7

Conservation

PhyloP100: 6.12
Variant links:
Genes affected
POT1 (HGNC:17284): (protection of telomeres 1) This gene is a member of the telombin family and encodes a nuclear protein involved in telomere maintenance. Specifically, this protein functions as a member of a multi-protein complex that binds to the TTAGGG repeats of telomeres, regulating telomere length and protecting chromosome ends from illegitimate recombination, catastrophic chromosome instability, and abnormal chromosome segregation. Increased transcriptional expression of this gene is associated with stomach carcinogenesis and its progression. Alternatively spliced transcript variants have been described. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Uncertain_significance. Variant got 2 ACMG points.

PP3
MetaRNN computational evidence supports a deleterious effect, 0.85

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
POT1NM_015450.3 linkuse as main transcriptc.670G>A p.Asp224Asn missense_variant 9/19 ENST00000357628.8

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
POT1ENST00000357628.8 linkuse as main transcriptc.670G>A p.Asp224Asn missense_variant 9/192 NM_015450.3 P1Q9NUX5-1

Frequencies

GnomAD3 genomes
AF:
0.000112
AC:
17
AN:
152102
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0000483
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.0000655
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000206
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.0000718
AC:
18
AN:
250680
Hom.:
0
AF XY:
0.0000517
AC XY:
7
AN XY:
135486
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.000159
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.000176
AC:
257
AN:
1458886
Hom.:
1
Cov.:
31
AF XY:
0.000167
AC XY:
121
AN XY:
725792
show subpopulations
Gnomad4 AFR exome
AF:
0.00
Gnomad4 AMR exome
AF:
0.0000224
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.000205
Gnomad4 OTH exome
AF:
0.000465
GnomAD4 genome
AF:
0.000112
AC:
17
AN:
152102
Hom.:
0
Cov.:
32
AF XY:
0.0000807
AC XY:
6
AN XY:
74308
show subpopulations
Gnomad4 AFR
AF:
0.0000483
Gnomad4 AMR
AF:
0.0000655
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.000206
Gnomad4 OTH
AF:
0.00
Alfa
AF:
0.000178
Hom.:
0
Bravo
AF:
0.000110
ESP6500AA
AF:
0.00
AC:
0
ESP6500EA
AF:
0.000116
AC:
1
ExAC
AF:
0.0000412
AC:
5

ClinVar

Significance: Uncertain significance
Submissions summary: Pathogenic:1Uncertain:7
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Uncertain:3
Uncertain significance, criteria provided, single submitterclinical testingCeGaT Center for Human Genetics TuebingenSep 01, 2023POT1: PM1, PP1, PS3:Supporting -
Uncertain significance, criteria provided, single submitterclinical testingGeneDxApr 30, 2024Observed in individuals with melanoma, chronic lymphocytic leukemia, and glioblastoma (PMID: 29522175, 34193977, 29625052, 36876055); Co-segregates with melanoma and/or hematologic malignancies in multiple families, but was also present in unaffected individuals (PMID: 29693246, 33216348, 24686846, 35977101); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 31919090, 32155570, 24784786, 25431349, 24686849, 27528712, 27365461, 26403419, 24686846, 25244922, 29693246, 29522175, 30556179, 32033110, 32987645, 32191290, 29625052, Szmyd2021, 34193977, 33216348, 36656928, 36539277, 28393830, 34218205, 36876055, 35977101, 36451132, 37183325, 37167549) -
Uncertain significance, criteria provided, single submitterclinical testingQuest Diagnostics Nichols Institute San Juan CapistranoNov 23, 2021The frequency of this variant in the general population, 0.00016 (20/128806 chromosomes in European (Non-Finnish) subpopulation, http://gnomad.broadinstitute.org), is higher than would generally be expected for pathogenic variants in this gene. In the published literature, the variant has been reported in individuals/families with melanoma or lymphoma and in their unaffected family members (PMIDs: 24686846 (2014), 27365461 (2016), 29522175 (2017), and 29693246 (2018)). This variant has also been detected in at least one individual with glioblastoma, one individual with lymphocytic leukemia and in individuals with lung adenocarcinoma (PMIDs: 29625052 (2018) and 31919090 (2020)). Functional studies have shown that this variant results in impaired telomeric binding in vitro and increased telomere length and fragility while the telomerase activity remains comparable to wild type and no significant increase in telomere dysfunction-induced damage foci is detected (PMID: 29693246 (2018)). Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is damaging. Based on the available information, we are unable to determine the clinical significance of this variant. -
Tumor predisposition syndrome 3 Pathogenic:1Uncertain:1
Pathogenic, no assertion criteria providedliterature onlyOMIMMay 01, 2014- -
Uncertain significance, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpJan 31, 2024This sequence change replaces aspartic acid, which is acidic and polar, with asparagine, which is neutral and polar, at codon 224 of the POT1 protein (p.Asp224Asn). This variant is present in population databases (rs202187871, gnomAD 0.01%). This missense change has been observed in individual(s) with cutaneous melanoma, glioblastoma multiforme, and/or Hodgkin lymphoma and other hematologic malignancies (PMID: 24686846, 29625052, 29693246, 33216348). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 139527). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt POT1 protein function with a negative predictive value of 80%. Experimental studies have shown that this missense change affects POT1 function (PMID: 29693246). RNA analysis performed to evaluate the impact of this missense change on mRNA splicing indicates it does not significantly alter splicing (Invitae). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Hereditary cancer-predisposing syndrome Uncertain:2
Uncertain significance, criteria provided, single submittercurationSema4, Sema4Mar 16, 2022- -
Uncertain significance, criteria provided, single submitterclinical testingAmbry GeneticsJan 23, 2024The p.D224N variant (also known as c.670G>A), located in coding exon 5 of the POT1 gene, results from a G to A substitution at nucleotide position 670. The aspartic acid at codon 224 is replaced by asparagine, an amino acid with highly similar properties. This alteration has been reported in multiple melanoma-prone families (Shi J et al. Nat. Genet., 2014 May;46:482-6; Artomov M et al. J. Natl. Cancer Inst., 2017 12;109) and in three siblings and a mother all affected with Hodgkin's lymphoma (McMaster ML et al. Br. J. Haematol., 2018 05;181:372-377). A recent study also identified this variant in a family affected by multiple cancer types, including cutaneous melanoma and hematopoietic syndromes- chronic myeloid leukemia (CML), Hodgkin's lymphoma, follicular lymphoma, and lentigo myeloid leukemia (LMM) (Nathan V. Br J Haematol. 2021 01;192(2):e57-e60). In a functional study, this alteration demonstrated deficient telomere binding in vitro and increased telomere length and fragility compared to wildtype cells (McMaster ML et al. Br. J. Haematol. 2018 05;181:372-377). This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
not specified Uncertain:1
Uncertain significance, criteria provided, single submitterclinical testingGenetic Services Laboratory, University of ChicagoJan 18, 2022DNA sequence analysis of the POT1 gene demonstrated a sequence change, c.670G>A, in exon 9 that results in an amino acid change, p.Asp224Asn. This sequence change has been described in the gnomAD database with a frequency of 0.016% in the non-Finnish European subpopulation (dbSNP rs202187871). This variant has been observed to segregate with melanoma in one family and with Hodgkin lymphoma in another family (PMID: 24686846, 29693246). Functional studies demonstrated that this sequence change affects protein function, leading to telomere lengthening and fragility (PMID: 29693246). The p.Asp224Asn change affects a highly conserved amino acid residue located in a domain of the POT1 protein that is not known to be functional. The p.Asp224Asn substitution appears to be deleterious using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL). Due to insufficient evidences, the clinical significance of the p.Asp224Asn change remains unknown at this time. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.90
BayesDel_addAF
Benign
-0.12
T
BayesDel_noAF
Benign
-0.17
CADD
Pathogenic
28
DANN
Pathogenic
1.0
DEOGEN2
Pathogenic
0.89
D;D;D
Eigen
Pathogenic
0.85
Eigen_PC
Pathogenic
0.83
FATHMM_MKL
Uncertain
0.96
D
LIST_S2
Uncertain
0.96
D;D;.
M_CAP
Uncertain
0.27
D
MetaRNN
Pathogenic
0.85
D;D;D
MetaSVM
Uncertain
0.17
D
MutationAssessor
Uncertain
2.7
M;.;.
MutationTaster
Benign
1.0
D;D
PrimateAI
Uncertain
0.54
T
PROVEAN
Uncertain
-3.1
D;D;.
REVEL
Pathogenic
0.81
Sift
Pathogenic
0.0
D;D;.
Sift4G
Pathogenic
0.0
D;D;D
Polyphen
1.0
D;.;.
Vest4
0.97
MVP
0.83
MPC
2.0
ClinPred
0.82
D
GERP RS
6.0
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.1
Varity_R
0.80
gMVP
0.93

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.16
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs202187871; hg19: chr7-124499043; COSMIC: COSV100714025; API